The result implied that the combination of Exo-siTMEM45A and palbociclib significantly benefited tumor CDK4/6 inhibitor therapy and the delivery of siTMEM45A by engineered exosomes might significantly reduce the use of palbociclib. This evidence concerns the gene CDK4 and neoplasm.